

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MURRAY et al.

Serial No. 10/519,922

Filed: January 3, 2005



Atty. Ref.: 620-354

Group: unknown

Examiner: unknown

For: 3-(HETERO) ARYLMETHOXY! PYRIDINES AND THEIR  
ANALOGUES AS P38 MAP KINASE INHIBITORS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

March 2, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:


- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

MURRAY, et al. .  
Serial No. 10/519,922

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-354

10/519,922

APPLICANT

MURRAY et al.

(Use several sheets if necessary)

FILING DATE

GROUP

January 3, 2005

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
EP 0 204 285 B1	01/1992	Europe			
EP 0 205 285 A1	12/1986	Europe			
EP 0 268 989 A1	06/1988	Europe			
EP 0 268 989 B1	06/1988	Europe			
EP 0 623 589 A1	11/1994	Europe			
EP 1 180 518 A1	02/2002	Europe			
JP 57-38777	03/1982	Japan			
WO 00/43773	07/2000	WIPO			
WO 00/55120	09/2000	WIPO			
WO 00/55139	09/2000	WIPO			
WO 00/55152	09/2000	WIPO			
WO 01/04115	01/2001	WIPO			
WO 01/12621	02/2001	WIPO			
WO 01/29041	04/2001	WIPO			

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Hall, et al., <i>Adv. Cancer Res.</i> , 68,67-108 (1996)
	Minden, et al., <i>Biochemica et Biophysica Acta</i> , 1333:F85-F104 (1997)
	Savelon, L., et al., <i>Bioorganic &amp; Medicinal Chemistry</i> , 9, 133-142 (1998)
	Burgess, G.S., et al., <i>Blood</i> , 92:2450-60 (1998)
	Frey and Mulder, <i>Cancer Res.</i> 57, 628-633 (1997)
	Hiles, et al., <i>Cell</i> , 70:419-429 (1992)
	Kunz, et al., <i>Cell</i> , 73:585-596 (1993)
	Rouse, et al., <i>Cell</i> 78, 1027-1037 (1994)
	Nurse, <i>Cell</i> , 91,865-867 (1997)
	Coghlan, et al., <i>Chemistry &amp; Biology</i> , 7, 793-803 (2000)
	Shokei, K., et al., <i>Circulation</i> , 97:1731-7 (1998)
	Force, T., et al., <i>Circ. Res.</i> , 78:947-53 (1996)
	Bogoyevitch, M.A., et al., <i>Circ. Res.</i> , 79:162-73 (1996)
	Adams, J.W., et al., <i>Circ. Res.</i> , 83: 167-78 (1998)
	O'Connor, <i>Cancer Surveys</i> , 29, 151-182 (1997)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-354

10/519,922

APPLICANT

MURRAY et al.

(Use several sheets if necessary)

FILING DATE

GROUP

January 3, 2005

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	WO 01/57022	08/2001	WIPO				
	WO 02/10146	02/2002	WIPO				
	WO 02/081475	10/2002	WIPO				
	WO 02/085859	10/2002	WIPO				
	WO 92/20642	11/1992	WIPO				
	WO 93/14081	07/1993	WIPO				
	WO 93/14082	07/1993	WIPO				
	WO 93/25571	12/1993	WIPO				
	WO 96/23783	08/1996	WIPO				
	WO 98/07425	02/1998	WIPO				
	WO 98/52558	11/1998	WIPO				
	WO 99/00357	01/1999	WIPO				
	WO 00/43384	07/2000	WIPO				
	WO 99/32433	07/1999	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Stover, et al., <i>Curr. Opin. Drug Disc. Dev.</i> , 2,274-285 (1999)
	Toledo, et al., <i>Curr. Med. Chem.</i> , 6, 775-805 (1999)
	McMahon, et al., <i>Current Opinion in Drug Discovery &amp; Development</i> , 1,131-146 (1998)
	Adams, et al., <i>Curr. Opin. Drug Disc. Dev.</i> , 2, 96-109 (1999)
	Kim and Kimmel, <i>Curr. Opinion Genetics Dev.</i> , 10, 508-514 (2000)
	Kumar, S., et al., <i>Curr Opin Pharmacol.</i> , 1(3), 307-13 (2001)
	Hay, D.P. and Sarau, H.M., <i>Curr. Opin. Pharmacol.</i> , 1: 242-7 (2001)
	Garcia-Bustos, et al., <i>EMBO J.</i> , 13:2352-2361 (1994)
	Gupta, et al., <i>EMBO J.</i> , 15:2760-70 (1996)
	Bischoff, et al., <i>EMBO J.</i> , 17, 3052-3065 (1998)
	Wilson, D.J., et al., <i>Eur. J. Immunol.</i> , 26:989-94 (1996)
	van Seventer, G.A., et al., <i>Bur. J. Immunol.</i> , 28:3867-77 (1998)
	Strawn, et al., <i>Exp. Opin. Invest. Drugs</i> , 7, 553-573 (1998)
	Hanks, S.K., Hunter, T., <i>FASEB J.</i> , 9:576-596 (1995)
	Neufeld, et al., <i>FASEB J.</i> , 13, 9-22 (1999)

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

10 Rec'd PCT/PTO 04 MAR 2005

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-354

10/519,922

APPLICANT

MURRAY et al.

(Use several sheets if necessary)

FILING DATE

GROUP

January 3, 2005

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 00/41698	07/2000	WIPO				
		WO 00/38675	07/2000	WIPO				
		WO 00/25791	05/2000	WIPO				
		WO 00/18738	04/2000	WIPO				
		WO 00/17175	03/2000	WIPO				
		WO 99/65897	12/1999	WIPO				
		WO 99/58502	11/1999	WIPO				
		WO 99/32455	07/1999	WIPO				
		WO 99/32463	07/1999	WIPO				
		WO 99/32111	07/1999	WIPO				
		WO 99/32436	07/1999	WIPO				
		WO 99/15164	04/1999	WIPO				
		WO 00/10563	03/2000	WIPO				
		WO 00/55120	09/2000	WIPO				
		WO 02/20642	03/2002	WIPO				
		WO 99/32110	07/1999	WIPO				
		WO 01/53274	07/2001	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Onishi, I., et al., <i>FEBS Lett.</i> , 420:201-4 (1997)
	Zwacka, R.M., et al., <i>Hepatology</i> , 28: 1022-30 (1998)
	Bjorbaek, et al., <i>J. Biol. Chem.</i> 270, 18848-18852 (1995)
	Kimura, et al., <i>J. Biol. Chem.</i> , 272, 13766-13771 (1997)
	Liang, F., et al., <i>J. Biol. Chem.</i> , 272:28050-6 (1997)
	Schumacher, et al., <i>J. Cell Biol.</i> , 143, 1635-1646 (1998)
	Haq, et al., <i>J. Cell Biol.</i> , 151, 117-129 (2000)
	Dinarello, <i>J. Clinical Immunology</i> , 5: 287-297 (1985)
	Xu, G., et al., <i>J. Clin. Invest.</i> , 97:508-14 (1996)
	Sivaraman, et al., <i>J. Clin. Invest.</i> 99, 1478-1483 (1997)
	Liu, Z-Y., et al., <i>J. Clin. Invest.</i> , 99:1798-804 (1997)
	Parola, M., et al., <i>J. Clin. Invest.</i> , 102:1942-50 (1998)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-354

10/519,922

APPLICANT

MURRAY et al.

(Use several sheets if necessary)

FILING DATE

GROUP

January 3, 2005

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Nishina, H., <i>et al.</i> , <i>J. Exp. Med.</i> , 186:941-53 (1997)
	Shaw, J.T., <i>et al.</i> , <i>J. Het. Chem.</i> , 17(1) 11-16 (1980)
	Ponticello, G.S., <i>et al.</i> , <i>J. Het. Chem.</i> , 17, 1980, 445-448 (Belstein 4435702)
	Kempiaki, J.J., <i>et al.</i> , <i>J. Immunol.</i> , 162:3176-87 (1999)
	Lin, A.J., <i>et al.</i> , <i>J. Med. Chem.</i> , 15, 615-618 (1972)
	Kaminski, J., <i>et al.</i> , <i>J. Med. Chem.</i> , 28(7), 1985, 876-892 (Belstein 4421226)
	Marchi, E., <i>et al.</i> , <i>J. Med. Chem.</i> , 28(7), 1985, 960-963 (Belstein 5938191)
	Giannotti, D., <i>et al.</i> , <i>J. Med. Chem.</i> , 34(4), 1356-1362 (1991)
	Namikawa, K., <i>et al.</i> , <i>The Journal of Neuroscience</i> , 20, 2875-2886 (2000)
	Berge <i>et al.</i> , 1977, "Pharmaceutically Acceptable Salts," <i>J. Pharm. Sci.</i> , Vol. 66, pp. 1-19
	Badger, <i>et al.</i> , <i>J. Pharm. Exp. Thera.</i> , 279: 1453-1461(1996)
	Carpino, L.A., <i>J. Am. Chem. Soc.</i> , (1993), 115(10), 4397-8
	Oarcfa-Echeverria, <i>et al.</i> , <i>Med. Res. Rev.</i> , 20, 28-57 (2000)
	Herlaar, E & Brown, Z., <i>Molecular Medicine Today</i> , 5: 439-447 (1999)
	Raingaud, <i>et al.</i> , <i>Mol. Cell Biol.</i> 16, 1247-1255 (1996)
	Martin, <i>et al.</i> , <i>Brain Res. Mol. Brain Res.</i> , 35:47-57 (1996)
	Anderson, <i>et al.</i> , <i>Nature</i> 343, 651-652 (1990)
	Yang <i>et al.</i> , <i>Nature</i> , 389:865-870 (1997)
	Zeng, <i>et al.</i> , <i>Nature</i> , 395, 507-510 (1998)
	Mohit, <i>et al.</i> , <i>Neuron</i> , 14:67-78 (1995)
	Behrens, A., <i>et al.</i> , <i>Nat. Genet.</i> , 21:326-9 (1999)
	Yuan, Z.Q., <i>et al.</i> , <i>Oncogene</i> , 19, 2324-2330 (2000)
	Bolen, <i>Oncogene</i> , 8, 2025-2031 (1993)
	Xu, X., <i>et al.</i> , <i>Oncogene</i> , 13:135-142 (1996)
	Griswold, <i>et al.</i> , <i>Pharmacol. Comm.</i> , 7: 323-229 (1996)
	Chen, <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 90, 10952-10956 (1993)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

